Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into a significant agreement to supply a range of glucagon-like peptide-1 (GLP-1) products to Hercules CM Newco Inc., a newly established US firm backed by a consortium of investors including Bain Capital Life Sciences, RTW Investments, Atlas Venture, and Lyra Capital.
According to Hengrui’s stock exchange announcement, Hercules will receive the rights to develop and commercialize several GLP-1 products globally, excluding Greater China. These products include the small-molecule GLP-1 receptor agonist HRS-7535, the peptide GLP-1/GIP dual receptor agonist injection, the oral product HRS9531, and the next-generation proinsulin product HRS-4729.
In return, Hengrui will receive a substantial upfront payment of USD 100 million and an additional USD 10 million in near-term milestone payments upon completion of technology transfer. Furthermore, Hengrui will be granted a 19.9% equity stake in Hercules. The deal also includes potential milestone payments of up to USD 200 million for clinical development and regulatory achievements, along with sales milestone payments of up to USD 5.725 billion tied to annual sales targets, bringing the total potential value of the agreement to over USD 6 billion.- Flcube.com
